Assembly Biosciences to Present Data on ABI-H0731 at AASLD 2016 Liver Meeting
11 nov. 2016 08h00 HE
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
Assembly Biosciences to Webcast Upcoming Investor Conferences
19 févr. 2016 07h30 HE
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Feb. 19, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut...
Assembly Biosciences to Describe Improved Methods for HBV Drug Development at Major International Meeting
06 oct. 2015 07h00 HE
|
Assembly Biosciences, Inc.
—Data to Be Presented at 2015 International Meeting on the Molecular Biology of Hepatitis B Describes Improved Methods for Measuring Key Biomarkers for Curative Therapies— —Assembly Also...
OnCore Biopharma Announces Exclusive HBV Research Collaboration With the Baruch S. Blumberg Institute
19 nov. 2014 07h00 HE
|
OnCore Biopharma, Inc.
DOYLESTOWN, Pa., Nov. 19, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biopharmaceutical company focused on the research, development and commercialization of oral...
OnCore Biopharma Agrees to Acquire Enantigen Therapeutics
01 oct. 2014 02h00 HE
|
OnCore Biopharma, Inc.
DOYLESTOWN, Pa., Oct. 1, 2014 (GLOBE NEWSWIRE) -- OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biotechnology company focused on the research, development and commercialization of oral...
OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection
09 sept. 2014 03h00 HE
|
OnCore Biopharma, Inc.
OnCore Secures Exclusive Worldwide Rights to NVP018
NVP018 Will Complement OnCore's Existing Pipeline Directed at Achieving All-Oral Cure for HBV
DOYLESTOWN, Pa., Sept. 9, 2014 (GLOBE NEWSWIRE)...
OnCore Biopharma Closes Series R Financing
05 sept. 2014 07h00 HE
|
OnCore Biopharma, Inc.
Funds to Expand OnCore's Portfolio of Oral Therapeutics for the Treatment of Chronic HBV
OnCore to Advance HBV Compounds Into Phase 1 Clinical Development During 2015
Former Pharmasset Team...